acimmune.com · 734
AC Immune SA is a global leader in developing precision medicine for neurodegenerative diseases, with a focus on conditions such as Alzheimer's and Parkinson's. The company utilizes cutting-edge technology platforms to pioneer new ways to diagnose, treat, and prevent neurodegeneration. AC Immune has received FDA Fast Track Designation for their anti-Abeta active immunotherapy ACI-24.060, aimed at treating Alzheimer's. They are also developing vaccine strategies to prevent both Alzheimer's and Parkinson's disease. AC Immune's technology platforms, Morphomer® and Supraantigen®, deliver top-tier small molecules and biologics. They have a broad pipeline focused on neurodegenerative diseases and are committed to pioneering precision medicine in the field. AC Immune is currently partnering on a Phase 3 study of Tau-PET diagnostic PI-2620 for Alzheimer's disease.
acimmune.com · years statistic
2003
1 | 0 |
2 | 0 |
3 | 0 |
4 | 1 |
5 | 0 |
6 | 1 |
7 | 0 |
8 | 1 |
9 | 0 |
10 | 1 |
11 | 0 |
12 | 1 |
2004
1 | 1 |
2 | 0 |
3 | 1 |
4 | 1 |
5 | 2 |
6 | 0 |
7 | 0 |
8 | 1 |
9 | 5 |
10 | 1 |
11 | 0 |
12 | 2 |
2005
1 | 1 |
2 | 3 |
3 | 3 |
4 | 0 |
5 | 0 |
6 | 0 |
7 | 1 |
8 | 0 |
9 | 0 |
10 | 1 |
11 | 1 |
12 | 2 |
2006
1 | 2 |
2 | 2 |
3 | 1 |
4 | 4 |
5 | 0 |
6 | 3 |
7 | 0 |
8 | 7 |
9 | 8 |
10 | 2 |
11 | 0 |
12 | 1 |
2007
1 | 0 |
2 | 0 |
3 | 0 |
4 | 0 |
5 | 0 |
6 | 0 |
7 | 0 |
8 | 1 |
9 | 1 |
10 | 6 |
11 | 0 |
12 | 1 |
2008
1 | 0 |
2 | 1 |
3 | 0 |
4 | 1 |
5 | 0 |
6 | 1 |
7 | 1 |
8 | 15 |
9 | 8 |
10 | 0 |
11 | 0 |
12 | 0 |
2010
1 | 0 |
2 | 0 |
3 | 0 |
4 | 0 |
5 | 0 |
6 | 0 |
7 | 0 |
8 | 0 |
9 | 3 |
10 | 3 |
11 | 1 |
12 | 3 |
2011
1 | 0 |
2 | 4 |
3 | 2 |
4 | 1 |
5 | 0 |
6 | 0 |
7 | 1 |
8 | 1 |
9 | 1 |
10 | 0 |
11 | 0 |
12 | 0 |
2012
1 | 0 |
2 | 0 |
3 | 0 |
4 | 1 |
5 | 0 |
6 | 1 |
7 | 0 |
8 | 0 |
9 | 0 |
10 | 0 |
11 | 1 |
12 | 0 |
2013
1 | 0 |
2 | 1 |
3 | 2 |
4 | 1 |
5 | 1 |
6 | 0 |
7 | 0 |
8 | 2 |
9 | 0 |
10 | 0 |
11 | 0 |
12 | 0 |
2014
1 | 0 |
2 | 0 |
3 | 1 |
4 | 0 |
5 | 1 |
6 | 0 |
7 | 0 |
8 | 1 |
9 | 0 |
10 | 0 |
11 | 0 |
12 | 1 |
2015
1 | 0 |
2 | 0 |
3 | 1 |
4 | 0 |
5 | 0 |
6 | 0 |
7 | 1 |
8 | 1 |
9 | 1 |
10 | 0 |
11 | 0 |
12 | 1 |
2016
1 | 3 |
2 | 1 |
3 | 2 |
4 | 1 |
5 | 1 |
6 | 4 |
7 | 1 |
8 | 2 |
9 | 2 |
10 | 3 |
11 | 1 |
12 | 0 |
2017
1 | 0 |
2 | 2 |
3 | 0 |
4 | 0 |
5 | 2 |
6 | 3 |
7 | 2 |
8 | 2 |
9 | 2 |
10 | 1 |
11 | 1 |
12 | 1 |
2018
1 | 1 |
2 | 1 |
3 | 4 |
4 | 5 |
5 | 6 |
6 | 4 |
7 | 4 |
8 | 10 |
9 | 6 |
10 | 5 |
11 | 7 |
12 | 5 |
2019
1 | 7 |
2 | 6 |
3 | 5 |
4 | 2 |
5 | 4 |
6 | 2 |
7 | 3 |
8 | 2 |
9 | 4 |
10 | 3 |
11 | 1 |
12 | 1 |
2020
1 | 0 |
2 | 1 |
3 | 0 |
4 | 26 |
5 | 14 |
6 | 16 |
7 | 22 |
8 | 26 |
9 | 35 |
10 | 29 |
11 | 21 |
12 | 1 |
2021
1 | 2 |
2 | 1 |
3 | 3 |
4 | 4 |
5 | 8 |
6 | 18 |
7 | 1 |
8 | 4 |
9 | 6 |
10 | 11 |
11 | 13 |
12 | 16 |
2022
1 | 11 |
2 | 3 |
3 | 9 |
4 | 13 |
5 | 13 |
6 | 10 |
7 | 9 |
8 | 8 |
9 | 11 |
10 | 8 |
11 | 5 |
12 | 7 |
2023
1 | 4 |
2 | 12 |
3 | 6 |
4 | 7 |
5 | 9 |
6 | 11 |
7 | 3 |
8 | 8 |
9 | 5 |
10 | 4 |
11 | 3 |
12 | 0 |
2024
1 | 2 |
2 | 1 |
3 | 2 |
4 | 1 |
5 | 0 |
6 | 0 |
7 | 0 |
8 | 0 |
9 | 0 |
10 | 0 |
11 | 0 |
12 | 0 |